Agreement with Dr. Reddy’s Laboratories doesn’t include its manufacture.
A nurse prepares to inoculate a volunteer with Russia’s brand-new coronavirus vaccine at a clinic in Moscow on September 10, 2020.|Image Credit:
Arrangement with Dr. Reddy’s Laboratories does not include its manufacture.
The Russia Direct Investment Fund (RDIF), which is piloting Russia’s Sputnik V prospect vaccine, currently in Phase 3 trials, has partnered with the Hyderabad-based Dr. Reddy’s Laboratories to evaluate, and subject to regulative approvals in India, supply 100 million dosages of the vaccine.
G.V. Prasad, co-chairman and handling director, Dr. Reddy’s Laboratories, said in a joint statement with RDIF: “We are happy to partner with RDIF to bring the vaccine to India. Researchers alert The Lancet to ‘possible information inconsistencies’ in Russian vaccine trial paper
On August 11, the Sputnik V vaccine, established by the Gamaleya National Research Study Institute of Public Health and Microbiology, was signed up by the Ministry of Health of Russia and became the world’s first signed up vaccine versus COVID-19 based on the human adenoviral vectors platform.